Serious Complications and Recurrence following Sacrospinous Ligament Fixation for the Correction of Apical Prolapse

J Clin Med. 2023 Jan 6;12(2):468. doi: 10.3390/jcm12020468.

Abstract

Objective: To evaluate the rates of serious complications and reoperation for recurrence following sacrospinous ligament fixation (SSLF) for apical pelvic organ prolapse. Methods: This was a national registry ancillary cohort comparative study. The VIGI-MESH registry includes data from 24 French health centers prospectively collected between May 2017 and September 2021. Time to occurrence of a serious complication or reoperation for genital prolapse recurrence was explored using the Kaplan-Meier curve and Log-rank test. The inverse probability of treatment weighting, based on propensity scores, was used to adjust for between-group differences. Results: A total of 1359 women were included and four surgical groups were analyzed: Anterior SSLF with mesh (n = 566), Anterior SSLF with native tissue (n = 331), Posterior SSLF with mesh (n = 57), and Posterior SSLF with native tissue (n = 405). Clavien-Dindo Grade III complications or higher were reported in 34 (2.5%) cases, with no statistically significant differences between the groups. Pelvic organ prolapse recurrence requiring re-operation was reported in 44 (3.2%) women, this was higher following posterior compared with anterior SSLF (p = 0.0034). Conclusions: According to this large database ancillary study, sacrospinous ligament fixation is an effective and safe surgical treatment for apical prolapse. The different surgical approaches (anterior/posterior and with/without mesh) have comparable safety profiles. However, the anterior approach and the use of mesh were associated with a lower risk of reoperation for recurrence compared with the posterior approach and the use of native tissue, respectively.

Keywords: apical prolapse; mesh repair; native tissue repair; pelvic organ prolapse; pelvic organ prolapse recurrence; sacrospinous ligament fixation; surgical complication; vaginal approach.

Grants and funding

This research work received funding from the Agence Nationale de Sécurité du Médicament et des Produits de Santé (France): Convention 2016S070/HAP 2016-Thématique 7-Projet VIGI-MESH.